RxDoctor Payments Data

Martand Chhibber, MD

Pain Medicine · Farmington, CTNPI 1184121717

Payments from drug & device makers

What this record shows

This record is dominated by travel and lodging: $1,919 of the $2,695 with a category attached, or 71.2%. Medtronic accounts for 71.2% of it on its own, with 10 other manufacturers making up the rest. Reporting peaked in 2022 at $1,919 and has fallen 93.8% since, to $119 in 2025.

$2,695in general payments, 2019–2025

Across 45 payments — averaging $59.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Boston Scientific$238
  • Collegium Pharmaceutical, Inc.$202
  • Pfizer$132
  • Scilex Pharmaceuticals Inc.$48
  • Idorsia Pharmaceuticals US Inc$31
  • plus $125 from 5 others

What the payments were for

  • Travel & lodging$1,91971%
  • Food & beverage$77629%

General payments by program year

22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,695 in reported general payments places this provider in the 55th percentile of 69 pain medicine providers in Connecticut.

See all pain medicine providers in Connecticut

Medicare billing

Part B allowed, 2024
$101,065
Medicare patients
247
Services billed
1,191

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RelistorMethylnaltrexone Bromide16$38,819
OxycontinOxycodone Hcl36$17,230
ZtlidoLidocaine24$16,046
BelbucaBuprenorphine Hcl23$13,253
Lidocaine133$9,935
Oxycodone Hcl269$4,770
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl20$3,592
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen132$2,733
Fentanyl19$2,019
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen126$1,976
Diclofenac Sodium41$1,724
Morphine Sulfate ErMorphine Sulfate74$1,351
Gabapentin124$1,130
Cyclobenzaprine Hcl42$946
Celecoxib20$722

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCRelistor$22$38,81916 claims
Scilex Pharmaceuticals Inc.Ztlido$48$16,04624 claims
Collegium Pharmaceutical, Inc.Belbuca$202$13,25323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 69 pain medicine providers in Connecticut.

Other pain medicine in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →